Altogether, TREM2 and FOLR2 might define two functionally distinct TAM populations, highlighting TAM heterogeneity in vivo and paving the way for TREM2 and FOLR2 targeting in BC patients. The gene discussed is FOLR2; the disease is breast cancer.